once weekly semaglutide in adults with alcohol use disorder A new study The Lancet is raising big questions about the future of treatment. Researchers tested once-weekly semaglutide, the drug sold as Wegovy, in people both obesity Semaglutide and Alcohol: Can It

Randomized controlled trials in *Obesity* and *Diabetes Care* show that patients achieving 1015% weight loss over 1218 months maintain that loss long-term, while those losing weight rapidly often regain it

A risk assessment matrix could provide a clearer picture of potential outcomes

Do not take NSAIDs if you have had or will undergo CABG surgery

Most palpitations on semaglutide are harmless and resolve within weeks as your body adapts

These differences may have implications for the sustainability of weight loss and warrant further investigation in long-term studies, particularly as it relates to potential effects on the central nervous system (7173)